Atossa Genetics Inc. (ATOS) Analysts See $-0.07 EPS

February 20, 2018 - By Adrian Mccoy

 Atossa Genetics Inc. (ATOS) Analysts See $ 0.07 EPS

Analysts expect Atossa Genetics Inc. (NASDAQ:ATOS) to report $-0.07 EPS on March, 15.They anticipate $0.70 EPS change or 90.91 % from last quarter’s $-0.77 EPS. After having $-0.17 EPS previously, Atossa Genetics Inc.’s analysts see -58.82 % EPS growth. The stock decreased 9.49% or $0.066 during the last trading session, reaching $0.625. About 2.69 million shares traded. Atossa Genetics Inc. (NASDAQ:ATOS) has declined 86.91% since February 20, 2017 and is downtrending. It has underperformed by 103.61% the S&P500.

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company has market cap of $19.89 million. The firm is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen for post-breast cancer and preventative therapy, as well as a potential therapy for breast density and other breast health conditions. It currently has negative earnings. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as makes and sells various medical devices primarily consisting of tools to assist breast surgeons.

More important recent Atossa Genetics Inc. (NASDAQ:ATOS) news were published by: which released: “Atossa Genetics to Present at Adoptive T-Cell Therapy Symposium – Molecular …” on February 13, 2018, also published article titled: “Atossa Genetics: Wait And See”, published: “Atossa Genetics Presents Additional Findings from its Phase 1 Study of Oral …” on February 01, 2018. More interesting news about Atossa Genetics Inc. (NASDAQ:ATOS) was released by: and their article: “Atossa Genetics to Host Conference Call to Present Additional Findings from …” with publication date: January 31, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: